The Burden of Cardiovascular Disease in Lymphoma Survivors: A Population-Based Matched Cohort Study
Main finding · CVD hospitalizationResult — go to the resultAverage adjusted HR 1.58 95% CI 1.52–1.64Authors' conclusion
Lymphoma survivors faced a persistently increased incidence of CVD compared to cancer-free individuals, and the absolute difference widened over the study period. The temporal risk patterns support current cardio-oncology guidelines recommending front-loaded and longitudinal cardiovascular surveillance.
Study context
- Population
- Adults diagnosed with lymphoma in Ontario, Canada (2007–2018), and cancer-free controlslymphoma survivors (median age 65, 45% female)
- Participants
- 36,334 adults
- Exposure
- Lymphoma survivors relative to cancer-free controls
- Lymphoma survivorsn = 36,334
- Outcome
- CVD hospitalization
- Follow-up
- Through March 2024
Methodological detailsmatched 1:1 to cancer-free controls by age and sex
- Matched 1:1 to cancer-free controls by age and sex
Main finding
As reported in the abstract
Average adjusted HR
1.58
95% CI 1.52–1.64
Lymphoma survivors vs cancer-free controls
average adjusted HR 1.58 (95% CI 1.52–1.64)
Observational data: associations, not effects.
Further findings
Absolute difference in cardiovascular disease (CVD) risk between lymphoma survivors and controls, by calendar period · 5 years
- 2007-2010
- 1.1% (95% CI: 0.3%-1.9%)
- 2015-2018
- 2.3% (95% CI: 1.6%-3.0%)
- Doubled from 2007-2010 to 2015-2018 (P = 0.02)
Original publication
The Burden of Cardiovascular Disease in Lymphoma Survivors: A Population-Based Matched Cohort Study. JACC Adv. Published 23 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →